Skip to content

Study · Animal study (in vivo) · rat · 2003

7 results

Des(1-3)IGF-1 treatment normalizes type 1 IGF receptor and phospho-Akt (Thr 308) immunoreactivity in predegenerative retina of diabetic rats.

Kummer A, Pulford BE, Ishii DN, Seigel GM

International journal of experimental diabesity research1 Jan 2003Cited by 15 (Europe PMC)

PMID12745670 (opens in a new tab)PMCIDPMC2480499 (opens in a new tab)DOI10.1080/15438600303729 (opens in a new tab)PepBankPUB-12745670
Download PDFPubMedAsk about this study
Jump to 7 results

Summary

Little is known about interventions that may prevent predegenerative changes in the diabetic retina. This study tested the hypothesis that immediate, systemic treatment with an insulin-like growth factor (IGF)-1 analog can prevent abnormal accumulations of type 1 IGF receptor, and phospho-Akt (Thr 308) immunoreactivity in predegenerative retinas of streptozotocin (STZ) diabetic rats. Type 1 IGF receptor immunoreactivity increased approximately 3-fold in both inner nuclear layer (INL) and ganglion cell layer (GCL) in retinas from STZ rats versus nondiabetic controls. Phospho-Akt (Thr 308) immunoreactivity increased 5-fold in GCL and 8-fold in INL of STZ rat retinas. In all cases, immunoreactive cells were significantly reduced in STZ des(1-3)IGF-1-treated versus STZ rats. Preliminary results suggested that vascular endothelial growth factor (VEGF) levels may also be reduced. Hyperglycemia/failure of weight gain in diabetic rats continued despite systemic des(1-3)IGF-1. These data show that an IGF-1 analog can prevent early retinal biochemical abnormalities implicated in the progression of diabetic retinopathy, despite ongoing hyperglycemia.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In diabetic rats, des(1‑3)IGF-1 reduced IGF receptor immunoreactivity in the inner nuclear layer versus untreated diabetic rats.

    In plain wordsIn rats with diabetes, des(1‑3)IGF-1 reduced retinal inner nuclear layer IGF receptor staining versus untreated diabetic rats.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseIGF receptor immunoreactivity in INL
    Study

    ratn: not reported in source

    streptozotocin diabetic rats
    Comparator
    STZ rats without des(1-3)IGF-1
    Outcome group
    Receptor activity and mechanism · Eye
    Studied dose
    Dose not stated · systemicAs given in this study (rat).

    Source sentences

    Summary
    In all cases, immunoreactive cells were significantly reduced in STZ des(1-3)IGF-1-treated versus STZ rats.
    2 context sentences
    Summary · context
    Type 1 IGF receptor immunoreactivity increased approximately 3-fold in both inner nuclear layer (INL) and ganglion cell layer (GCL) in retinas from STZ rats versus nondiabetic controls.
    Summary · context
    This study tested the hypothesis that immediate, systemic treatment with an insulin-like growth factor (IGF)-1 analog can prevent abnormal accumulations of type 1 IGF receptor, and phospho-Akt (Thr 308) immunoreactivity in predegenerative retinas of streptozotocin (STZ) diabetic rats.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In diabetic rats, des(1‑3)IGF-1 reduced IGF receptor immunoreactivity in the ganglion cell layer versus untreated diabetic rats.

    In plain wordsIn rats with diabetes, des(1‑3)IGF-1 reduced retinal ganglion cell layer IGF receptor staining versus untreated diabetic rats.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseIGF receptor immunoreactivity in GCL
    Study

    ratn: not reported in source

    streptozotocin diabetic rats
    Comparator
    STZ rats without des(1-3)IGF-1
    Outcome group
    Receptor activity and mechanism · Eye
    Studied dose
    Dose not stated · systemicAs given in this study (rat).

    Source sentences

    Summary
    In all cases, immunoreactive cells were significantly reduced in STZ des(1-3)IGF-1-treated versus STZ rats.
    2 context sentences
    Summary · context
    Type 1 IGF receptor immunoreactivity increased approximately 3-fold in both inner nuclear layer (INL) and ganglion cell layer (GCL) in retinas from STZ rats versus nondiabetic controls.
    Summary · context
    This study tested the hypothesis that immediate, systemic treatment with an insulin-like growth factor (IGF)-1 analog can prevent abnormal accumulations of type 1 IGF receptor, and phospho-Akt (Thr 308) immunoreactivity in predegenerative retinas of streptozotocin (STZ) diabetic rats.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In diabetic rats, des(1‑3)IGF-1 reduced phospho-Akt immunoreactivity in the ganglion cell layer versus untreated diabetic rats.

    In plain wordsIn rats with diabetes, des(1‑3)IGF-1 reduced retinal ganglion cell layer phospho-Akt staining versus untreated diabetic rats.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreasePhospho-Akt immunoreactivity in GCL
    Study

    ratn: not reported in source

    streptozotocin diabetic rats
    Comparator
    STZ rats without des(1-3)IGF-1
    Outcome group
    Receptor activity and mechanism · Eye
    Studied dose
    Dose not stated · systemicAs given in this study (rat).

    Source sentences

    Summary
    In all cases, immunoreactive cells were significantly reduced in STZ des(1-3)IGF-1-treated versus STZ rats.
    2 context sentences
    Summary · context
    Phospho-Akt (Thr 308) immunoreactivity increased 5-fold in GCL and 8-fold in INL of STZ rat retinas.
    Summary · context
    This study tested the hypothesis that immediate, systemic treatment with an insulin-like growth factor (IGF)-1 analog can prevent abnormal accumulations of type 1 IGF receptor, and phospho-Akt (Thr 308) immunoreactivity in predegenerative retinas of streptozotocin (STZ) diabetic rats.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In diabetic rats, des(1‑3)IGF-1 reduced phospho-Akt immunoreactivity in the inner nuclear layer versus untreated diabetic rats.

    In plain wordsIn rats with diabetes, des(1‑3)IGF-1 reduced retinal inner nuclear layer phospho-Akt staining versus untreated diabetic rats.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreasePhospho-Akt immunoreactivity in INL
    Study

    ratn: not reported in source

    streptozotocin diabetic rats
    Comparator
    STZ rats without des(1-3)IGF-1
    Outcome group
    Receptor activity and mechanism · Eye
    Studied dose
    Dose not stated · systemicAs given in this study (rat).

    Source sentences

    Summary
    In all cases, immunoreactive cells were significantly reduced in STZ des(1-3)IGF-1-treated versus STZ rats.
    2 context sentences
    Summary · context
    Phospho-Akt (Thr 308) immunoreactivity increased 5-fold in GCL and 8-fold in INL of STZ rat retinas.
    Summary · context
    This study tested the hypothesis that immediate, systemic treatment with an insulin-like growth factor (IGF)-1 analog can prevent abnormal accumulations of type 1 IGF receptor, and phospho-Akt (Thr 308) immunoreactivity in predegenerative retinas of streptozotocin (STZ) diabetic rats.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In diabetic rats, preliminary results suggested that des(1‑3)IGF-1 may reduce VEGF levels.

    In plain wordsIn rats with diabetes, preliminary results suggested that des(1‑3)IGF-1 may reduce VEGF levels.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseVEGF levels
    Study

    ratn: not reported in source

    streptozotocin diabetic rats
    Comparator
    STZ rats without des(1-3)IGF-1
    Outcome group
    Receptor activity and mechanism · Eye
    Studied dose
    Dose not stated · systemicAs given in this study (rat).

    Source sentences

    Summary
    Preliminary results suggested that vascular endothelial growth factor (VEGF) levels may also be reduced.
    1 context sentence
    Summary · context
    This study tested the hypothesis that immediate, systemic treatment with an insulin-like growth factor (IGF)-1 analog can prevent abnormal accumulations of type 1 IGF receptor, and phospho-Akt (Thr 308) immunoreactivity in predegenerative retinas of streptozotocin (STZ) diabetic rats.

Studies that did not test the peptide alone2

In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  1. 06AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Efficacy outcome

    In diabetic rats, hyperglycemia persisted despite systemic des(1‑3)IGF-1.

    In plain wordsIn rats with diabetes, high blood glucose persisted despite systemic des(1‑3)IGF-1.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    Direction not reportedPersistent hyperglycemia
    Study

    ratn: not reported in source

    streptozotocin diabetic rats
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Hyperglycemia/failure of weight gain in diabetic rats continued despite systemic des(1-3)IGF-1.
    1 context sentence
    Summary · context
    This study tested the hypothesis that immediate, systemic treatment with an insulin-like growth factor (IGF)-1 analog can prevent abnormal accumulations of type 1 IGF receptor, and phospho-Akt (Thr 308) immunoreactivity in predegenerative retinas of streptozotocin (STZ) diabetic rats.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  2. 07AnimalNot a test of IGF-1 DES (des(1-3)IGF-I) aloneAnimal study (in vivo)Efficacy outcome

    In diabetic rats, failure of weight gain persisted despite systemic des(1‑3)IGF-1.

    In plain wordsIn rats with diabetes, failure to gain weight persisted despite systemic des(1‑3)IGF-1.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    Direction not reportedFailure of weight gain
    Study

    ratn: not reported in source

    streptozotocin diabetic rats
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Hyperglycemia/failure of weight gain in diabetic rats continued despite systemic des(1-3)IGF-1.
    1 context sentence
    Summary · context
    This study tested the hypothesis that immediate, systemic treatment with an insulin-like growth factor (IGF)-1 analog can prevent abnormal accumulations of type 1 IGF receptor, and phospho-Akt (Thr 308) immunoreactivity in predegenerative retinas of streptozotocin (STZ) diabetic rats.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:52 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.